Lilly Shifts Gears In China With New Shanghai-based R&D Center

Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip